Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Completed

• Conditions: Spondyloarthrosis
• Interventions: Drug: Etanercept

• Registration Number: NCT04507776
• Lead Sponsor: Pfizer

Brief Summary

This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology Center)

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-27
• Study First Submitted QC: 2020-08-10
• Study First Posted: 2020-08-11
• Study Start: 2020-09-01
• Primary Completion: 2020-10-01
• Study Completion: 2020-10-01
• Status Verified: 2021-09
• Results First Submitted: 2021-09-03
• Results First Submitted QC: 2021-09-03
• Last Update Submitted: 2021-09-03
• Results First Posted: 2021-10-04
• Last Update Posted: 2021-10-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 763

Inclusion Criteria

• Diagnosed SpA patients
• 18 years of age and older.
• Did not receive previous other biological treatments.
• Patients have at least 1 year on Enbrel.

Read More

Exclusion Criteria

• Had previously used another biological treatments.
• Use of etanercept for less than 1 year duration.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with spondyloarthropathies	Etanercept	Patients with spondyloarthrosis that received Etanercept as treatment for disease

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With 7 Years Adherence to Etanercept	7 years [from the data retrieved and observed in 1 month of this study]	In this outcome measure, percentage of participants who continued etanercept treatment and adhered to the treatment for 7 years were reported.

Trial Locations

Locations (1)

Pfizer; 🇮🇶 Baghdad, Iraq